[425] Penumbra Inc Business Combination Communication
Rhea-AI Filing Summary
Filed by Boston Scientific Corporation
Pursuant to Rule 425 under the Securities Act of 1933
Deemed filed pursuant to 14a-12 under the Securities Exchange Act of 1934
Subject Company: Penumbra, Inc.
Commission File No.: 001-37557
Date: January 15, 2026
On January 15, 2026, Boston Scientific Corporation made the below communication on its LinkedIn account:
Today we announced a definitive agreement to acquire Penumbra, Inc. a leading innovator in mechanical thrombectomy and neurovascular therapies. Penumbra's comprehensive portfolio includes differentiated devices to treat conditions such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia. heart attack and aneurysms. "Penumbra is a well-established company with an experienced, high-performing team and this acquisition offers Boston Scientific an opportunity to enter new, fast-growing segments within the vascular space," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "I'm thrilled to combine the talents and shared values of our teams and expand access for these novel technologies to more patients and customers around the world."
